Año 2022 / Volumen 114 / Número 12
Original
Hepatitis C virus infection screening reduces mortality and is cost-effective independently of the intervention test

731-737

DOI: 10.17235/reed.2022.8609/2022

David Nicolás Pérez, Dalia Elena Morales Arráez, Iván Castilla Rodríguez, Fernando Gutiérrez Nicolás, Felicitas Díaz-Flores Estévez, Antonia de Vera González, Gloria Julia Nazco Casariego, Manuel Hernández Guerra,

Resumen
Introduction: Chronic infection due to hepatitis C virus (HCV) is frequently asymptomatic even in advanced stages of liver disease. Implementation of a screening program based on different HCV tests may enable an earlier diagnosis of HCV liver disease and subsequent application of highly effective treatment. Patients & methods: A Markov model which compares three different screening strategies for hepatitis C versus no screening in low-risk prevalence (general population) and high-risk prevalence population (people who inject drugs or prison population) was designed, taking into account age at the start of screening and participation. The three strategies were: 1) serological detection of antibodies against the HCV, 2) dried blood spot test (DBS) to detect antibodies against HCV and 3) detection of RNA from HCV. Quality-adjusted life-years (QALY) were taken as a measurement of effectiveness. The incremental cost-effectiveness ratio (ICER) was calculated and a deterministic and probabilistic sensitivity analysis was performed. Results: All three screening strategies were found to be cost-effective with an ICER of €13,633, €12,015 and €12,328/QALY for AntiHCV, DBS-AntiHCV and DBS-RNA HCV, respectively. There was a decrease in mortality due to liver disease in comparison to no screening for AntiHCV (40.7% and 52%), DBS-AntiHCV (45% and 80%) and DBS-RNA HCV (45.2% and 80%) for low-prevalence and high-prevalence populations, respectively. Conclusion: All test interventions for HCV screening are cost-effective for the early detection of HCV infection, also achieving a reduction in mortality. Thus, implementation of screening programs for HCV should not be halted by decisions on monetary policy.
Share Button
Nuevo comentario
Comentarios
No hay comentarios para este artículo.
Artículos relacionados

Artículo Especial

Estrategia para la Eliminación de la Hepatitis C en Cantabria

DOI: 10.17235/reed.2020.7108/2020

Editorial

Cribado del cáncer colorrectal y supervivencia

DOI: 10.17235/reed.2018.5870/2018

Instrucciones para citar
Nicolás Pérez D, Morales Arráez D, Castilla Rodríguez I, Gutiérrez Nicolás F, Díaz-Flores Estévez F, de Vera González A, et all. Hepatitis C virus infection screening reduces mortality and is cost-effective independently of the intervention test. 8609/2022


Descargar en un gestor de citas

Descargue la cita de este artículo haciendo clic en uno de los siguientes gestores de citas:

Métrica
Este artículo ha sido visitado 935 veces.
Este artículo ha sido descargado 134 veces.

Estadísticas de Dimensions


Estadísticas de Plum Analytics

Ficha Técnica

Recibido: 15/01/2022

Aceptado: 07/03/2022

Prepublicado: 14/03/2022

Publicado: 12/12/2022

Tiempo de revisión del artículo: 48 días

Tiempo de prepublicación: 58 días

Tiempo de edición del artículo: 331 días


Compartir
Este artículo aun no tiene valoraciones.
Valoración del lector:
Valora este artículo:




Asociación Española de Ecografía Digestiva Sociedad Española de Endoscopia Digestiva Sociedad Española de Patología Digestiva
La REED es el órgano oficial de la Sociedad Española de Patología Digestiva, la SociedadEspañola de Endoscopia Digestiva y la Asociación Española de Ecografía Digestiva
Política de cookies Política de Privacidad Aviso Legal © Copyright 2023 y Creative Commons. Revista Española de Enfermedades Digestivas